Sensor-equipped pill raises technological, ethical questions

November 17, 2017 by Linda Loyd, The Philadelphia Inquirer
Credit: Arek Socha, Qimono, CC0 Public Domain

The first drug with a sensor embedded in a pill that alerts doctors when patients have taken their medications was approved by the Food and Drug Administration, raiding issues involving privacy, cost, and whether patients really want caregivers looking over their shoulders.

Japan's Otsuka Pharmaceutical Co. will insert a tiny chip - the size of a grain of sand - inside the psychiatric medication Abilify used to treat schizophrenia and other serious .

The is a breakthrough in allowing others to see whether patients are taking their medicines as prescribed, but also raises privacy concerns. Forty percent to 45 percent of people with common cardiovascular and other chronic diseases such as diabetes do not take their medications as prescribed.

"That's a big deal because medication non-adherence is a huge public-health challenge in the United States," said Kevin Volpp, a physician and director of the University of Pennsylvania's Center for Health Incentives and Behavioral Economics.

The tablet, Abilify MyCite, contains a digital sensor that is activated by stomach fluids, sending a signal to a patch worn by the patient, which, in turn, notifies a smartphone app that the medication has been taken. The information can be shared with physicians and others with the goal of keeping doctors more informed in making treatment decisions.

But the pill is not magic. People still have to take it, and the skin patch has to be replaced every seven days.

The technology is likely to be controversial. "There's an open question of how paternalistic do we want our to be," Volpp said. "Many patients, for whatever reasons, may decide, 'I don't want to take the .' Having their provider, or , monitor closely whether they are taking the medicines on a daily basis may be uncomfortable to some patients."

Niteesh Choudhry, a physician at Brigham & Women's Hospital in Boston and a professor at Harvard Medical School, said: "This is a technological feat. There's a lot to be celebrated here from a purely technological perspective. That said, there are a ton of unknowns."

First, will the technological monitoring be reliable, and will the data improve patients' taking their medications? "We really don't know anything about that yet," Choudhry said.

Will patients feel better, be hospitalized less often, and function better? "Those clinical outcomes, some of which are very patient-centric, need to ultimately be established," Choudhry said.

The technology raises a medical ethics issue: What will the information collected from the devices be used for?

The problem of people not taking their medications is "a normal human behavior, like not exercising, or following a diet," Choudhry said. "For some patients, this technology will almost certainly be helpful and useful. But it may not be applicable for all , nor for all conditions."

The new pill will likely cost more than the existing Abilify, or generic versions. "So there's a trade-off between the advantages that a new technology like this one offers, and the cost that is added because we have to pay for the technology," he said.

Otsuka and partner Proteus Digital Health plan to introduce the treatment to some health plans and providers, who will identify a "limited" number of adults with schizophrenia, bipolar disorder, or who may benefit. Patients can choose not to share some information, or opt out at any time, the companies said.

Ken Duckworth, medical director for the National Alliance on Mental Illness, called the new pill "a tool that we don't know how to use yet. But it has the potential, if a person wants to communicate information to a family member, or their doctor, that they are taking their medicine.

"Sometimes people with schizophrenia spend a lot of time convincing people that they are actually taking the medicine. This is one way to accomplish that," Duckworth said.

"It might also help doctors answer the question: 'Was this medicine successful?' One question with all medications, not just for schizophrenia, is did this person take the medicine?" he said. "It's important because if the person didn't take the medicine, it's hard to conclude that it was a failed treatment. But if he took the medicine, and continued to have symptoms, then you can make a change in the regimen."

If the technology is commercially successful, Volpp said "there will be a lot of other companies working on this."

"I think there are some clear clinical applications here. It will be interesting to see how this unfolds and whether this gets extended to other types of medications," Volpp said.

Explore further: US regulators approve first digital pill to track patients

1 shares

Related Stories

US regulators approve first digital pill to track patients

November 14, 2017
U.S. regulators have approved the first drug with a sensor that alerts doctors when the medication has been taken, offering a new way of monitoring patients but also raising privacy concerns.

Listening to the patient's voice: A more patient-centered approach to medication safety

November 16, 2017
Communication between patients and clinicians that is patient-centered, taking into account patient concerns and preferences has important implications for patient safety.

This 'smart pill' can help patients remember their meds

July 26, 2017
Forget to take your medication? Now you can get a reminder to find your pills - sent by the pill itself.

Low-income patients more likely to take blood pressure medication when doctor involves them in conversation

August 22, 2017
The key to getting low-income patients to take their blood pressure medications as prescribed may be as simple as a conversation. Low-income patients with high blood pressure were less likely to take their medications as ...

Plan A is to get patients to stick to their blood pressure pills

January 19, 2017
There is value in starting off patients with high blood pressure on an all-in-one pill. In the long run, it may help them stick to taking the potentially life-saving medicines prescribed to them. This advice is given to clinicians ...

Study asks: To improve patients' health, should you pay physicians, patients, or both?

November 8, 2015
Providing financial incentives to both primary care physicians and patients leads to a greater reduction in low-density lipoprotein (LDL) cholesterol in patients than paying only the physician or only the patient, according ...

Recommended for you

Shortcut strategy for screening compounds with clinical potentials for drug development

December 4, 2018
Developing a new drug often takes years and costs hundreds of millions of dollars. A shortcut has now been reported in a study led by City University of Hong Kong (CityU), which can potentially reduce the time and costs of ...

Drug wholesalers drove fentanyl's deadly rise, report concludes

December 4, 2018
Fentanyl, a powerful synthetic opioid implicated in nearly 29,000 overdose deaths in the United States last year, most likely spread because of heroin and prescription pill shortages, and also because it was cheaper for drug ...

Global review reports on administration of children's antibiotics

December 4, 2018
Researchers analyzing the sales of oral antibiotics for children in 70 high- and middle-income countries found that consumption varies widely from country to country with little correlation between countries' wealth and the ...

Opioid prescriptions from dentists linked to youth addiction risk

December 3, 2018
Teens and young adults who receive their initial opioid prescriptions from their dentists or oral surgeons are at increased risk for opioid addiction in the following year, a study from the Stanford University School of Medicine ...

Rise in meth and opioid use during pregnancy

November 29, 2018
Amphetamine and opioid use in pregnancy increased substantially over the last decade in the United States, a new Michigan Medicine-led study finds. And a disproportionate rise occurred in rural counties.

Mouse model aids study of immunomodulation

November 19, 2018
Because mice do not respond to immunomodulatory drugs (IMiDs), preclinical therapeutic and safety studies of the effects of IMiDs have not been possible in existing types of mice. This has led to an inability to accurately ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.